Leukemia & Lymphoma Society CEO Goes Totally Baldacious
Still fundraising to meet his $50,000 goal, The Leukemia & Lymphoma Society President and CEO, John Walter, showed just how serious he was about showing solidarity with cancer patients by "shaving one for the team today."
Do you know someone with cancer? Have you wondered how you can show your support? Here’s a great way to demonstrate your love:
Go Totally Baldacious. When you “Shave one for the Team” you show your solidarity with cancer patients, raise awareness about cancer, and help raise money for The Leukemia & Lymphoma Society.
So guys, shave your heads. Gals, lighten up or color your hair to honor someone with cancer. If you’re already bald, wear a temporary tattoo, shave your face or get creative.
You can also mix it up! Guys can color their hair. Gals can shave. Bald yourself virtually. However you want to do it is great. We’re all on the same Team here, people.
To find out more, go to:
http://www.facebook.com/baldacious
to register yourself, go to:
http://totallybaldacious.llsevent.org/pages/index.cfm?PageID=63123
to give to John Walter’s campaign, go to:
http://totallybaldacious.llsevent.org/pledge/index.cfm?mid=CEOJOHNWALTER
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
